Raised voices, accusations, drama and controversy marked last week’s four-day meetings, convened by the U.S. Environmental Protection Agency (EPA) to determine whether or not regulators should re-approve glyphosate, the key ingredient in Monsanto’s Roundup herbicide, for use in the U.S.
Reporting for Huffington Post, US Right to Know’s Carey Gillam wrote:
The EPA’s determination is crucial on many fronts - Monsanto is currently defending itself against more than three dozen lawsuits claiming glyphosate-based Roundup gave people non-Hodgkin lymphoma (NHL), a type of blood cancer; both the EPA and the European Union are assessing re-registrations of glyphosate to determine if limits should be placed on the chemical; and Monsanto is attempting a $66 billion merger with German-based Bayer.
Below are a few reports from the meetings last week. But the bottom line is this: Is there anyone in the EPA who has the will to do what we, the taxpayers, pay them to do? Which is to place a higher priority on the health and rights of the people, than on the profits of Monsanto?
We won’t know for at least another three months. But this we do know: The stakes are high.